KR102741437B1 - Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 - Google Patents
Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 Download PDFInfo
- Publication number
- KR102741437B1 KR102741437B1 KR1020207029906A KR20207029906A KR102741437B1 KR 102741437 B1 KR102741437 B1 KR 102741437B1 KR 1020207029906 A KR1020207029906 A KR 1020207029906A KR 20207029906 A KR20207029906 A KR 20207029906A KR 102741437 B1 KR102741437 B1 KR 102741437B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- methyl
- carboxamide
- pyridin
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646432P | 2018-03-22 | 2018-03-22 | |
| US62/646,432 | 2018-03-22 | ||
| PCT/US2019/023111 WO2019183186A1 (en) | 2018-03-22 | 2019-03-20 | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200135425A KR20200135425A (ko) | 2020-12-02 |
| KR102741437B1 true KR102741437B1 (ko) | 2024-12-10 |
Family
ID=66001366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207029906A Active KR102741437B1 (ko) | 2018-03-22 | 2019-03-20 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11597721B2 (https=) |
| EP (1) | EP3768667B1 (https=) |
| JP (1) | JP7485609B2 (https=) |
| KR (1) | KR102741437B1 (https=) |
| CN (1) | CN111936486B (https=) |
| ES (1) | ES2944733T3 (https=) |
| WO (1) | WO2019183186A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3118094A1 (en) * | 2018-10-30 | 2020-05-07 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| DK4038063T3 (da) * | 2020-03-11 | 2024-05-21 | Beijing Innocare Pharma Tech Co Ltd | Heterocykliske forbindelser til inhibering af tyk2-aktiviteter |
| US20230295119A1 (en) | 2020-04-14 | 2023-09-21 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| WO2022135430A1 (en) | 2020-12-22 | 2022-06-30 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| EP4308556A4 (en) | 2021-03-16 | 2025-02-19 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| CN115141149A (zh) * | 2021-03-30 | 2022-10-04 | 浙江文达医药科技有限公司 | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 |
| CN116888125B (zh) * | 2021-04-07 | 2024-04-12 | 上海齐鲁制药研究中心有限公司 | Tyk2抑制剂及其用途 |
| AU2022268464B2 (en) * | 2021-05-04 | 2025-04-17 | Shanghai Zheye Biotechnology Co. Ltd. | Nitrogen-containing heterocyclic pyridine compound |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| TWI825800B (zh) * | 2021-06-22 | 2023-12-11 | 大陸商南京明德新藥研發有限公司 | 亞磺醯亞胺類化合物及其應用 |
| WO2023284869A1 (zh) * | 2021-07-15 | 2023-01-19 | 南京明德新药研发有限公司 | 含硫/磷的芳基类化合物及其应用 |
| EP4387964A1 (en) * | 2021-08-21 | 2024-06-26 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| WO2023064223A1 (en) | 2021-10-11 | 2023-04-20 | Gossamer Bio Services, Inc. | Tri-substituted pyridines |
| JP2024539280A (ja) | 2021-10-25 | 2024-10-28 | カイメラ セラピューティクス， インコーポレイテッド | Ｔｙｋ２分解剤およびそれらの使用 |
| EP4448514A4 (en) | 2021-12-16 | 2025-10-29 | Lynk Pharmaceuticals Co Ltd | TYK2 INHIBITORS AND ASSOCIATED COMPOSITIONS AND PROCESSES |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| WO2024020221A1 (en) * | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| WO2024131882A1 (zh) * | 2022-12-22 | 2024-06-27 | 南京明德新药研发有限公司 | 一种吡啶多取代化合物的盐型、晶型及其制备方法 |
| CN120607493B (zh) * | 2025-06-04 | 2026-04-24 | 江西科技师范大学 | 一种含嘧啶结构的酰胺类化合物及其在制备tyk2 jh2激酶抑制剂中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2013104573A1 (en) | 2012-01-10 | 2013-07-18 | F. Hoffmann-La Roche Ag | Pyridazine amide compounds and their use as syk inhibitors |
| US9315494B2 (en) | 2012-11-08 | 2016-04-19 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| MY194668A (en) * | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| CN110267964B (zh) | 2016-12-13 | 2022-05-03 | 百时美施贵宝公司 | 作为IL-12、IL-23及/或IFNα响应调节剂的经取代的杂芳基氧化膦化合物 |
-
2019
- 2019-03-20 EP EP19715330.7A patent/EP3768667B1/en active Active
- 2019-03-20 WO PCT/US2019/023111 patent/WO2019183186A1/en not_active Ceased
- 2019-03-20 US US16/982,937 patent/US11597721B2/en active Active
- 2019-03-20 KR KR1020207029906A patent/KR102741437B1/ko active Active
- 2019-03-20 CN CN201980020946.5A patent/CN111936486B/zh active Active
- 2019-03-20 JP JP2020550632A patent/JP7485609B2/ja active Active
- 2019-03-20 ES ES19715330T patent/ES2944733T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3768667B1 (en) | 2023-04-12 |
| US20210032220A1 (en) | 2021-02-04 |
| CN111936486A (zh) | 2020-11-13 |
| EP3768667A1 (en) | 2021-01-27 |
| JP7485609B2 (ja) | 2024-05-16 |
| CN111936486B (zh) | 2023-09-22 |
| ES2944733T3 (es) | 2023-06-23 |
| KR20200135425A (ko) | 2020-12-02 |
| US11597721B2 (en) | 2023-03-07 |
| WO2019183186A1 (en) | 2019-09-26 |
| JP2021518389A (ja) | 2021-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102741437B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 | |
| JP7490107B2 (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| JP6458038B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 | |
| TWI582077B (zh) | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 | |
| JP7097875B2 (ja) | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物 | |
| EP3917912B1 (en) | Amide-disubstituted pyridine or pyridazine compounds | |
| WO2021222153A1 (en) | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators | |
| JP7145850B2 (ja) | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なヘテロ二環化合物 | |
| JP2020502268A (ja) | Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物 | |
| KR102865925B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 | |
| EA046543B1 (ru) | Амидзамещенные гетероциклические соединения | |
| EA041710B1 (ru) | Сульфон-, пиридин-, алкил-, амидзамещенные гетероарильные соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201019 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220318 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240520 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241203 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20241206 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20241206 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |